Aspen Neuroscience has raised $70 million to advance the development of Parkinson’s disease therapies using patients’ own cells.
The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression. This approach is referred to as an autologous neuron replacement therapy.